Navigation Links
Next Safety Releases Advanced Respirator for Infectious Diseases
Date:8/5/2009

JEFFERSON, N.C., Aug. 5 /PRNewswire/ -- Next Safety, Inc. (NSI) announces advanced respirators that give people more confidence to go to work in a pandemic environment. Next Safety is releasing for sale to the public respirator products the company developed for the bird flu influenza A subtype H5N1.

The respirators were originally developed for the bird flu (H5N1), which never became contagious. The Next Safety respirators are now being sold to the public for the first time. These respirators are a cross functional platform that supply highly purified air to half facemasks and air supply hoods.

Next Safety designed its respirators with input from the CDC and the World Health Organization along from the US army's famed AMRIID bioterrorism warfare center.

Next Safety's core competence is the development, design and rapid production of pulmonary products like its 9000 series respirators. Next Safety respirators are rated for 30,000 hours of continuous operation.

Next Safety respirator products are fabricated from battlefield-grade medical plastics. Next Safety uses compound filters that do not fail. Texas Instruments and EBM-Pabst power Next Safety's respirator products.

As with all respirator products, to be effective, Next Safety respirators must be used with proper eye protection and with a well-defined and understood decontamination program.

Next Safety is a leader in the development of pulmonary health products. It has a product line of advanced respirators that were developed for many different applications.

The company also develops pulmonary drug delivery products. It is a leader in the development of nicotine delivery devices for smoking cessation and nicotine replacement products.

Next Safety has 28 US patents that are either issued are pending for its products.

Next Safety is also developing other pulmonary drug delivery platforms for inhaled antibiotics and anti-medics, concentrated narcotics and drugs to treat pulmonary conditions such as asthma, COPD and the immune compromised.

The doctors, scientists and engineers who work for Next Safety have developed the most comprehensive and effective solution for the pulmonary delivery of medicines to in-home patients and persons who are addicted to smoking cigarettes. The company is developing combined respirator and pulmonary drug delivery systems for soldiers to have highly sophisticated medical care that greatly enhances their likely hood of survival in battle.

Next Safety engineers are experts in high-volume manufacturing. The company's engineers and managers have made more than 40 million electrical devices a month for years. These are products that are designed to protect babies and children.

Next Safety has invested in significant capacity for pandemic stockpiling. The company expects to build approximately 5 million respirators for delivery in December 2009 and has the capacity to build 300 million respirators a month for pandemic stockpiling by March 2010.

Next Safety thanks the doctors and staff at Italy's level-4 Milan biological research center for helping it design the best respirators for pandemic stockpiling.

Next Safety's advanced respirator product line is available at http://www.nextsafety.com.

    Contact:

    Eric Hunter
    336-246-7700
   http://www.nextsafety.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Next Safety, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
2. Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements
6. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
7. iCardiac Selected for Multiple Cardiac Safety Studies
8. Assessment of safety and efficacy of human embryonic stem cell therapy
9. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
10. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
11. Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
Breaking Biology Technology:
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. and ... business relationship that includes integrating Syngrafii,s patented LongPen™ ... project. This collaboration will result in greater convenience ... credit union, while maintaining existing document workflow and ... ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):